Michael Zelefsky Net Worth

Michael Zelefsky biography

Dr. Michael J. Zelefsky M.D. serves as Independent Director of the Company. Dr. Zelefsky has served as a member of our Board of Directors since June 2017. Dr. Zelefsky has served as a Member at Memorial Sloan-Kettering Cancer Center Department of Radiation Oncology since 2005. He has served as Chief of Memorial Sloan-Kettering’s Brachytherapy Service since 2000, and has been a Professor of Radiation Oncology at Weill Cornell Medical College, Cornell University since 1994. He is a recognized expert in radiation therapy and has helped develop and enhance Memorial Sloan-Kettering’s prostate brachytherapy program during his tenure. Dr. Zelefsky received a Bachelor of Arts in Biology (summa cum laude) from Yeshiva University in 1982 and a Medical Doctor degree from Albert Einstein College of Medicine in 1986. Dr. Zelefsky is currently Editor-in-Chief of Brachytherapy and has previously served as president of the American Brachytherapy Society. Based on Dr. Zelefsky’s extensive experience and background in oncology, the Board of Directors believes that Dr. Zelefsky has the appropriate set of skills to serve as a member of the Board.

What is the salary of Michael Zelefsky?

As the Independent Director of Mustang Bio Inc, the total compensation of Michael Zelefsky at Mustang Bio Inc is $100,000. There are 6 executives at Mustang Bio Inc getting paid more, with Dr. Manuel Litchman having the highest compensation of $606,871.

How old is Michael Zelefsky?

Michael Zelefsky is 59, he's been the Independent Director of Mustang Bio Inc since 2017. There are 3 older and 5 younger executives at Mustang Bio Inc. The oldest executive at Mustang Bio Inc is Dr. Manuel Litchman, 67, who is the Pres, CEO & Director.

Insiders trading at Mustang Bio Inc

Over the last 7 years, insiders at Mustang Bio Inc have traded over $122,072 worth of Mustang Bio Inc stock and bought 951,208 units worth $2,853,591 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss a Manuel Md Litchman. On average, Mustang Bio Inc executives and independent directors trade stock every 89 days with the average trade being worth of $15,504. The most recent stock trade was executed by Manuel Md Litchman on 18 March 2022, trading 10,000 units of MBIO stock currently worth $6,300.

What does Mustang Bio Inc do?

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.

Mustang Bio Inc executives and stock owners

Mustang Bio Inc executives and other stock owners filed with the SEC include:

• Dr. Manuel Litchman,
  Pres, CEO & Director
• Manuel Litchman,
  President, Chief Executive Officer, Director
• Brian Achenbach,
  Senior Vice President - Finance, Corporate Controller
• Brian K. Achenbach M.B.A.,
  Sr. VP of Fin. & Corp. Controller
• Adam Chill,
  Independent Director
• Michael Weiss,
  Executive Chairman of the Board
• Michael Zelefsky,
  Independent Director
• Neil Herskowitz,
  Independent Director
• Lindsay Rosenwald,
  Director
• Michael S. Weiss Esq.,
  Exec. Chairman
• Robyn M. Hunter,
  Corp. Sec.
• Dr. Bruce Dezube M.D.,
  Sr. VP & Head of Clinical Devel.
• Scott Smith M.B.A.,
  Exec. Director and Head of Alliance & Program Management
• Lynn E. Bayless,
  Head of Regulatory Affairs
• Debra Manning SPHR,
  VP of HR
• Matthew Wein J.D.,
  VP & Gen. Counsel
• Dr. Knut Niss,
  Chief Technology Officer
• Biotech, Inc. Fortress,
  10% owner